公开(公告)号：US20120202240A1

公开(公告)日：2012-08-09

申请号：US13387572

申请日：2010-07-23

申请人： Hans-Peter Deigner ,  Matthias Kohl ,  David Enot ,  Theresa Koal ,  Matthias Keller

发明人： Hans-Peter Deigner ,  Matthias Kohl ,  David Enot ,  Theresa Koal ,  Matthias Keller

IPC分类号： G01N27/62 ,  G01R33/48 ,  G06F19/00 ,  H01J49/26 ,  G01N27/72

CPC分类号： G01N33/6893 ,  G01N2800/26 ,  G16B5/00 ,  G16B40/00 ,  Y10T436/173845

摘要： The present invention relates to a reliable and statistically significant method for predicting the likelihood of an onset of an inflammation associated organ failure from a biological sample of a mammalian subject in vitro, by means of a subject's quantitative metabolomics profile comprising a plurality of endogenous metabolites, and comparing it with a quantitative reference metabolomics profile of a plurality of endogenous organ failure predictive target metabolites in order to predict whether the subject is likely or unlikely to develop an organ failure. Furthermore, the invention relates to the usefulness of endogenous organ failure predictive target metabolites in such a method.

摘要翻译： 本发明涉及用于通过受试者的定量代谢组学谱来预测来自哺乳动物受试者的体外生物样品的炎症相关器官功能衰竭发作的可能性的可靠和统计学上显着的方法，所述定量代谢组学特征包括多种内源性代谢物， 并将其与多种内源性器官衰竭预测目标代谢物的定量参考代谢组学谱进行比较，以便预测受试者是否可能或不可能发生器官功能衰竭。 此外，本发明涉及在这种方法中内源性器官衰竭预测目标代谢物的有用性。